TherapeuticsMD Inc (NASDAQ:TXMD) was upgraded by research analysts at CIBC from a “market perform” rating to an “outperform” rating in a research note issued on Tuesday, July 11th.

TXMD has been the subject of a number of other research reports. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $15.00 target price on shares of TherapeuticsMD in a research report on Monday, April 17th. Cantor Fitzgerald restated an “overweight” rating and set a $33.00 price target on shares of TherapeuticsMD in a report on Wednesday, May 10th. Zacks Investment Research cut TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Wednesday, May 3rd. Jefferies Group LLC set a $15.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, June 14th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 target price on shares of TherapeuticsMD in a report on Monday, April 24th. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $16.14.

TherapeuticsMD (TXMD) traded up 3.08% during midday trading on Tuesday, hitting $5.36. 2,136,740 shares of the stock traded hands. TherapeuticsMD has a 1-year low of $3.50 and a 1-year high of $8.30. The company has a 50-day moving average of $5.36 and a 200-day moving average of $5.53. The stock’s market cap is $1.09 billion.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. The company had revenue of $4.25 million during the quarter, compared to the consensus estimate of $4.91 million. TherapeuticsMD had a negative return on equity of 71.36% and a negative net margin of 530.84%. The firm’s revenue was down 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.11) earnings per share. On average, equities analysts expect that TherapeuticsMD will post ($0.45) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/08/07/cibc-upgrades-therapeuticsmd-inc-nasdaqtxmd-to-outperform-updated-updated-updated.html.

Large investors have recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. raised its stake in shares of TherapeuticsMD by 56.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock valued at $207,000 after buying an additional 10,330 shares during the period. Greenwood Capital Associates LLC raised its position in TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock worth $146,000 after buying an additional 3,022 shares during the last quarter. JPMorgan Chase & Co. raised its position in TherapeuticsMD by 2.5% in the first quarter. JPMorgan Chase & Co. now owns 13,725,853 shares of the company’s stock worth $98,827,000 after buying an additional 329,245 shares during the last quarter. Stifel Financial Corp raised its position in TherapeuticsMD by 125.4% in the first quarter. Stifel Financial Corp now owns 429,362 shares of the company’s stock worth $3,091,000 after buying an additional 238,885 shares during the last quarter. Finally, American International Group Inc. raised its position in TherapeuticsMD by 7.1% in the first quarter. American International Group Inc. now owns 92,415 shares of the company’s stock worth $665,000 after buying an additional 6,103 shares during the last quarter.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.